Compare AU
Compare DRUG vs. SLF
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare Currency Hedged ETF (DRUG) and the SPDR S&P/ASX 200 Listed Property Fund (SLF). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | SLF | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 61 | 19 |
Median incremental investment | $920.50 | $4,004.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,892.10 | $3,906.30 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | SLF | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | SLF.AX was created on 2002-02-15 by SPDR. The fund's investment portfolio concentrates primarily on real estate equity. The ETF currently has 561.84m in AUM and 22 holdings. The Investment Manager uses a passive investment strategy, investing in a portfolio of securities designed to reflect the characteristics of each Funds Index..The S&P/ASX 200 A-REIT Index is a sub-index of the S&P/ASX 200 Index and provides exposure to Australian Real Estate Investment Trusts |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | Goodman Group (42.81 %) Scentre Group (11.09 %) Stockland Corp Ltd (7.24 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Real Estate (100.00 %) Other (2.07 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | Australia (100.00 %) |
Management fee | 0.57 % | 0.16 % |
Key Summary
DRUG | SLF | |
|---|---|---|
Issuer | BetaShares | SPDR |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | S&P/ASX 200 A-REIT Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.16 % |
Price | $7.95 | $13.47 |
Size | $185.172 million | $523.466 million |
10Y return | N/A | 16.93 % |
Annual distribution yield (5Y) | 1.90 % | 6.76 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 18/02/2002 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | SLF | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 61 | 19 |
Median incremental investment | $920.50 | $4,004.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,892.10 | $3,906.30 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | SLF | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | SLF |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |